Drug Type Hematopoietic stem cell therapy |
Synonyms- |
Target- |
Action- |
Mechanism Stem cell replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1/2 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Retinal Vein Occlusion | Phase 2 | United States | 22 Oct 2019 |
Phase 1/2 | 16 | Sham Therapy+Autologous Bone Marrow CD34+ Stem Cells (Immediate Cellular Therapy / Deferred Sham Therapy) | aicaphvqzo = rxgfngdhjk iwyydnguco (eixnmqyzuk, bcmoyzrwun - gwuopylgsj) View more | - | 02 Dec 2024 | ||
Sham Therapy+Autologous Bone Marrow CD34+ Stem Cells (Immediate Sham Therapy / Deferred Cellular Therapy) | aicaphvqzo = lzfzaxsouu iwyydnguco (eixnmqyzuk, oltmcrsbgg - kvsnccafws) View more |





